MDGL - Madrigal Pharmaceuticals Inc Stock Price, Fair Value and News

207.37USD-10.59 (-4.86%)Delayed as of 08 May 2024, 03:03 pm ET

Market Summary

USD207.37-10.59

Delayedas of 08 May 2024, 03:03 pm

-4.86%

MDGL Alerts

5 major insider sales recently.

MDGL Stock Price

View Fullscreen

MDGL RSI Chart

MDGL Valuation

Market Cap

4.6B

Price/Earnings (Trailing)

-10.46

Price/Sales (Trailing)

12.8K

Price/Free Cashflow

-11.88

MDGL Price/Sales (Trailing)

MDGL Profitability

Return on Equity

-52.22%

Return on Assets

-41.05%

Free Cashflow Yield

-8.42%

MDGL Fundamentals

MDGL Revenue

Revenue (TTM)

363.0K

MDGL Earnings

Earnings (TTM)

-444.3M

Earnings Growth (Yr)

-91.87%

Earnings Growth (Qtr)

-31.51%

Breaking Down MDGL Revenue

52 Week Range

133.66302.68

(Low)(High)

Last 7 days

6.8%

Last 30 days

-10.3%

Last 90 days

15.6%

Trailing 12 Months

-29.4%

How does MDGL drawdown profile look like?

MDGL Financial Health

Current Ratio

9.39

Debt/Equity

0.14

Debt/Cashflow

-3.35

MDGL Investor Care

Shares Dilution (1Y)

16.53%

Diluted EPS (TTM)

-23.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2021	2.6M	1.5M	743.0K	363.0K
2020	9.9M	8.1M	6.1M	4.3M
2019	10.0M	11.8M	11.8M	11.0M
2018	1.2M	2.3M	4.9M	7.7M
2017	0	0	0	558.0K
2016	0	0	0	0
2012	0	0	0	0
2011	12.4M	9.9M	8.2M	7.6M
2010	0	101.1M	58.0M	14.8M
2009	0	0	0	144.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Madrigal Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 08, 2024	taub rebecca	acquired	25,288	9.45	2,676	pres., r&d, and cmo
Apr 08, 2024	friedman paul a	sold	-6,467,490	246	-26,270	-
Apr 08, 2024	friedman paul a	acquired	248,252	9.45	26,270	-
Apr 08, 2024	taub rebecca	sold	-658,258	245	-2,676	pres., r&d, and cmo
Apr 05, 2024	taub rebecca	acquired	259,932	9.45	27,506	pres., r&d, and cmo
Apr 05, 2024	friedman paul a	acquired	260,943	9.45	27,613	-
Apr 05, 2024	friedman paul a	sold	-6,721,080	243	-27,613	-
Apr 05, 2024	taub rebecca	sold	-6,693,790	243	-27,506	pres., r&d, and cmo
Apr 04, 2024	taub rebecca	acquired	175,175	9.45	18,537	pres., r&d, and cmo
Apr 04, 2024	taub rebecca	sold	-4,502,820	242	-18,537	pres., r&d, and cmo

Which funds bought or sold MDGL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	Parallel Advisors, LLC	unchanged	-	2,959	22,164	-%
May 06, 2024	SG Americas Securities, LLC	new	-	360,000	360,000	-%
May 06, 2024	HighTower Advisors, LLC	added	53.93	162,000	370,000	-%
May 06, 2024	TEACHER RETIREMENT SYSTEM OF TEXAS	added	6.55	132,000	704,000	-%
May 06, 2024	Quantbot Technologies LP	new	-	26,704	26,704	-%
May 06, 2024	Candriam S.C.A.	reduced	-33.33	-1,440,820	4,806,720	0.03%
May 03, 2024	FNY Investment Advisers, LLC	new	-	554,000	554,000	0.33%
May 03, 2024	SIGNATUREFD, LLC	added	3.92	4,705	28,306	-%
May 03, 2024	VICTORY CAPITAL MANAGEMENT INC	added	10.83	124,011	568,261	-%
May 03, 2024	Riggs Asset Managment Co. Inc.	new	-	535	535	-%

Are Funds Buying or Selling MDGL?

Are funds buying MDGL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MDGL

No. of Funds

MDGL Alerts

5 major insider sales recently.

Unveiling Madrigal Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 25, 2024	baker bros. advisors lp	9.99%	2,070,544	SC 13D/A
Feb 14, 2024	armistice capital, llc	0.25%	50,000	SC 13G/A
Feb 14, 2024	avoro capital advisors llc	9.9%	2,288,888	SC 13G/A
Feb 14, 2024	paulson & co. inc.	5.6%	-	SC 13G/A
Feb 13, 2024	janus henderson group plc	14.7%	2,902,050	SC 13G/A
Feb 13, 2024	vanguard group inc	7.98%	1,574,742	SC 13G/A
Jan 29, 2024	blackrock inc.	6.1%	1,212,562	SC 13G/A
Jan 22, 2024	state street corp	3.55%	700,739	SC 13G/A
Dec 13, 2023	bay city capital llc	2.9%	567,644	SC 13D/A
Nov 21, 2023	baker bros. advisors lp	9.99%	1,987,702	SC 13D/A

Recent SEC filings of Madrigal Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	424B3	Prospectus Filed
May 07, 2024	424B5	Prospectus Filed
May 07, 2024	8-K	Current Report
May 07, 2024	8-K	Current Report
May 07, 2024	S-3ASR	S-3ASR
Apr 29, 2024	DEFA14A	DEFA14A
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	ARS	ARS
Apr 10, 2024	4	Insider Trading

Peers (Alternatives to Madrigal Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

Madrigal Pharmaceuticals Inc News

Latest updates

Madrigal Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4
Revenue	-13.3%	52,000	60,000	91,000	160,000	432,000	823,000	1,204,000	1,870,000	2,214,000	2,766,000	3,005,000	3,039,000	2,979,000	2,821,000	1,166,000	705,000	216,000	174,000	92,000	76,000	59,000
Operating Expenses	2.3%	64,601,000	63,160,000	61,742,000	52,979,000	59,555,000	58,786,000	50,327,000	38,005,000	29,954,000	24,195,000	22,704,000	18,119,000	14,454,000	11,333,000	7,826,000	-	-	-	-	-	-
S&GA Expenses	41.3%	11,712,000	8,287,000	10,110,000	7,209,000	6,126,000	5,494,000	5,639,000	4,605,000	5,044,000	4,748,000	7,110,000	5,746,000	5,583,000	5,122,000	2,717,000	1,871,000	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-2.3%	-64,549,000	-63,100,000	-61,651,000	-52,546,000	-59,123,000	-57,963,000	-49,023,000	-36,135,000	-27,740,000	-21,429,000	-19,699,000	-15,080,000	-11,475,000	-8,512,000	-6,460,000	-	-	-	-	-	-
Net Income Margin	-109.4%	-666	-318	-153	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-5.6%	-48,164,000	-45,606,000	-46,883,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	69.0%	1,082	641	238	302	332	363	159	216	223	273	305	328	310	287	340	388	411	442	456	470	480
Current Assets	68.5%	1,074	637	235	302	331	361	157	215	221	272	303	326	308	285	338	387	409	440	455	469	478
Cash Equivalents	523.0%	623	100	62.00	77.00	113	332	59.00	53.00	42.00	36.00	49.00	34.00	44.00	54.00	109	62.00	67.00	47.00	89.00	73.00	47.00
Net PPE	12.2%	2.00	2.00	1.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
Liabilities	-1.6%	232	235	216	199	182	165	148	133	77.00	77.00	70.00	57.00	49.00	47.00	50.00	45.00	26.00	25.00	16.00	13.00	11.00
Current Liabilities	-3.5%	114	119	100	100	98.00	116	99.00	84.00	77.00	77.00	69.00	57.00	49.00	47.00	49.00	45.00	26.00	25.00	15.00	12.00	10.00
Long Term Debt	0.6%	116	115	115	99.00	84.00	49.00	49.00	49.00	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	115	115	99.00	84.00	49.00	49.00	49.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	109.9%	851	405	22.00	104	150	197	11.00	84.00	146	196	235	271	261	240	290	343	385	417	440	457	469
Retained Earnings	-11.0%	-1,483	-1,336	-1,224	-1,125	-1,039	-962	-876	-795	-724	-667	-602	-539	-478	-425	-366	-308	-259	-223	-195	-174	-154
Additional Paid-In Capital	34.1%	2,335	1,741	1,246	1,229	1,190	1,160	888	880	871	863	838	810	739	665	656	650	644	640	636	631	623
Shares Outstanding	0%	20.00	20.00	18.00	18.00	18.00	18.00	17.00	17.00	17.00	17.00	17.00	17.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	3,158	-	-	-	985	-	-	-	819	-	-	-	1,130	-	-	-	884	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-86.6%	-149,157	-79,933	-84,920	-75,310	-84,067	-58,515	-59,069	-57,360	-49,913	-48,051	-45,556	-46,881	-43,429	-54,947	-47,850	-24,258	-30,506	-12,282	-11,324	-11,540	-6,478
Share Based Compensation	34.0%	19,902	14,852	12,660	10,973	11,250	8,082	8,122	7,944	7,477	6,356	6,242	8,179	6,096	5,134	5,061	5,689	4,846	4,032	4,950	7,755	6,022
Cashflow From Investing	127.1%	98,053	-362,123	50,199	-3,732	-186,864	66,387	65,137	19,236	55,926	15,643	40,091	-27,325	-33,464	-4,798	94,753	19,365	50,460	-30,507	28,267	36,438	-3,491
Cashflow From Financing	19.5%	573,706	479,916	19,580	42,930	52,690	264,337	-	49,114	-	19,503	21,099	63,541	67,094	4,629	350	109	-	-	35.00	117	83.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MDGL Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	3 Months Ended								12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Operating expenses:
Research and development	70,640,000	70,951,000	68,605,000	62,154,000	70,742,000	68,271,000	58,499,000	47,929,000	272,350,000	245,441,000	205,164,000
General and administrative	46,536,000	27,583,000	17,845,000	16,182,000	14,557,000	12,141,000	11,774,000	9,658,000	108,146,000	48,130,000	37,318,000
Total operating expenses	117,176,000	98,534,000	86,450,000	78,336,000	85,299,000	80,412,000	70,273,000	57,587,000	380,496,000	293,571,000	242,482,000
Loss from operations	(117,176,000)	(98,534,000)	(86,450,000)	(78,336,000)	(85,299,000)	(80,412,000)	(70,273,000)	(57,587,000)	(380,496,000)	(293,571,000)	(242,482,000)
Interest income	8,953,000	3,298,000	3,551,000	3,776,000	1,076,000	717,000	323,000	69,000	19,578,000	2,185,000	363,000
Interest expense	(3,971,000)	(3,504,000)	(2,901,000)	(2,336,000)	(1,682,000)	(1,502,000)	(780,000)	0	(12,712,000)	(3,964,000)	0
Other income	0	0	0	0	0	0	0	0	0	0	273,000
Net loss	$ (112,194,000)	$ (98,740,000)	$ (85,800,000)	$ (76,896,000)	$ (85,905,000)	$ (81,197,000)	$ (70,730,000)	$ (57,518,000)	$ (373,630,000)	$ (295,350,000)	$ (241,846,000)
Net loss per common share:
Basic net loss per common share (in dollars per share)	$ (5.68)	$ (5.34)	$ (4.69)	$ (4.23)	$ (4.98)	$ (4.75)	$ (4.14)	$ (3.36)	$ (19.99)	$ (17.23)	$ (14.63)
Diluted net loss per common share (in dollars per share)	$ (5.68)	$ (5.34)	$ (4.69)	$ (4.23)	$ (4.98)	$ (4.75)	$ (4.14)	$ (3.36)	$ (19.99)	$ (17.23)	$ (14.63)
Basic weighted average number of common shares outstanding (in shares)	19,760,842	18,476,414	18,310,952	18,187,924	17,237,517	17,103,395	17,103,395	17,103,395	18,687,774	17,137,201	16,535,188
Diluted weighted average number of common shares outstanding (in shares)	19,760,842	18,476,414	18,310,952	18,187,924	17,237,517	17,103,395	17,103,395	17,103,395	18,687,774	17,137,201	16,535,188

MDGL Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 99,915,000	$ 331,549,000
Marketable securities	534,216,000	27,225,000
Prepaid expenses and other current assets	3,150,000	2,595,000
Total current assets	637,281,000	361,369,000
Property and equipment, net	1,553,000	601,000
Right-of-use asset	1,713,000	602,000
Total assets	640,547,000	362,572,000
Current liabilities:
Accounts payable	28,041,000	23,831,000
Accrued expenses	89,980,000	91,461,000
Lease liability	527,000	602,000
Total current liabilities	118,548,000	115,894,000
Long term liabilities:
Loan payable, net of discount	115,480,000	49,289,000
Lease liability	1,186,000	0
Total long term liabilities	116,666,000	49,289,000
Total liabilities	235,214,000	165,183,000
Stockholders’ equity:
Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at December 31, 2023 and December 31, 2022; 2,369,797 and 2,369,797 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	0	0
Common stock, par value $0.0001 per share authorized: 200,000,000 at December 31, 2023 and December 31, 2022; 19,875,427 and 18,102,523 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	2,000	2,000
Additional paid-in-capital	1,741,153,000	1,160,079,000
Accumulated other comprehensive income (loss)	468,000	(32,000)
Accumulated deficit	(1,336,290,000)	(962,660,000)
Total stockholders’ equity	405,333,000	197,389,000
Total liabilities and stockholders’ equity	$ 640,547,000	$ 362,572,000

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.

WEBSITE	madrigalpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	92

Madrigal Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Madrigal Pharmaceuticals Inc? What does MDGL stand for in stocks?

MDGL is the stock ticker symbol of Madrigal Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Madrigal Pharmaceuticals Inc (MDGL)?

As of Tue May 07 2024, market cap of Madrigal Pharmaceuticals Inc is 4.65 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MDGL stock?

You can check MDGL's fair value in chart for subscribers.

What is the fair value of MDGL stock?

You can check MDGL's fair value in chart for subscribers. The fair value of Madrigal Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Madrigal Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MDGL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Madrigal Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether MDGL is over valued or under valued. Whether Madrigal Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Madrigal Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MDGL.

What is Madrigal Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, MDGL's PE ratio (Price to Earnings) is -10.46 and Price to Sales (PS) ratio is 12.8 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MDGL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Madrigal Pharmaceuticals Inc's stock?

In the past 10 years, Madrigal Pharmaceuticals Inc has provided 0.042 (multiply by 100 for percentage) rate of return.